<DOC>
	<DOCNO>NCT02097108</DOCNO>
	<brief_summary>This 24-week , one arm , open-label , interventional , non-comparative multicenter study evaluate lipid change HIV infect woman hyperlipidemia boost PI base regimen switch boost PI raltegravir standard dosage 400mg twice daily . This study aim study effect metabolic profile switch hyperlipidemic HIV infect woman PI base regimen raltegravir .</brief_summary>
	<brief_title>Changes Lipids Lipoproteins HIV Infected Women After Switch From Protease Inhibitor Raltegravir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Documented HIV1 infection female patient , age ≥18 year Patients receive antiretroviral therapy consist least 2 antiretroviral agent protease inhibitor plus ritonavirboosted protease inhibitor ( PI ) least previous 6 month Plasma HIV viral load &lt; 50 copies/ml current boost PI contain regimen ≥ 6 month prior study entry Fasting LDL cholesterol &gt; 130 mg/dl Fasting triglycerides &lt; 450 mg/dl History virological failure previous antiretroviral therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Switch</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Women</keyword>
</DOC>